Abstract
Specific cell surface receptors present in abundance on tumor cells have been used for targeted therapies of antibodies. Antibody based therapies involving antibody recruiting molecules (ARM) for treatment of cancer are selective and have low occurrence of side effects. The therapeutic potential of these therapies can be made more efficient by utilizing endogenously present antibodies in human serum. Herein we designed, synthesized and evaluated the potential of a novel ARM having folic acid as a targeting ligand and l-rhamnose as antibody recruiting molecule, linked via a tetraethylene glycol moiety. Exposure of tumor cells to the conjugate resulted in efficient and cell specific binding which was observed using alkyne as a reporter through click chemistry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
